AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03361098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide 5 microgram b.i.d. week 1-4 Exenatide 10 microgram b.i.d. week 5-16
Study NCT03361098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide 5 microgram b.i.d. week 1-4 Exenatide 10 microgram b.i.d. week 5-16
Study NCT03361098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo exenatide
Description: placebo b.i.d. exenatide
Study NCT03361098 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo exenatide
Description: placebo b.i.d. exenatide
Study NCT03361098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo dapagliflozin
Description: placebo tablets dapagliflozin
Study NCT03361098 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo dapagliflozin
Description: placebo tablets dapagliflozin
Study NCT03623477 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation (CRT)
Description: Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The cognitive remediation therapy group will complete computerized training activities in attention, memory, processing speed, problem solving, and executive functions.
Study NCT03623477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRT+ Social Cognition Training
Description: Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The combined cognitive remediation and social cognition training group will complete computerized training that target neurocognitive functions, facial affect emotion recognition and mentalizing tasks.
Study NCT02005068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Description: The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.
Study NCT02650986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02650986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT02650986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02650986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study NCT02650986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
Description: Given IV
Study NCT03228342 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MusculoSkeletal Ultrasound
Description: Patient will be assess with ultrasound (GUS-7 score) and the results will be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization.
Study NCT03228342 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MusculoSkeletal Ultrasound
Description: Patient will be assess with ultrasound (GUS-7 score) and the results will not be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization.
Study NCT05629247 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Systematic screening of immune deficiency
Description: Systematic screening of immune deficiency with blood tests
Study NCT04185987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leone slide low friction elastomeric ligature
Description: Leone slide low friction elastomeric ligature application
Study NCT04185987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RMO tough - o energy elastomeric ligature
Description: RMO tough - o energy elastomeric ligature application
Study NCT04185987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentsply sili tie elastomeric ligature
Description: Dentsply sili tie elastomeric ligature application
Study NCT04185987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AO twisted ended ligature wire
Description: AO twisted ended ligature wire application
Study NCT03187353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: Stimulant medications are used to reduce interruptive behavior, fidgeting, and other hyperactive symptoms, as well as help a person finish tasks and improve his or her relationships for adults who have ADHD. Please note that the FDA has not approved the use of Vyvanse® for the treatment of memory and concentration difficulties related to medically induced menopause.
Study NCT03187353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: The placebo capsule will be filled with microcellulose.
Study NCT03478046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: Compare the total and temporal changes in fetuin-A phosphorylation and insulin resistance that occur with an 8 to 10% weight loss induced by chronic exercise training and dietary modification
Study NCT01664923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg, daily, by mouth.
Study NCT01664923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: 50 mg, daily, by mouth
Study NCT02740361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprexis, DeprexisPlus
Description: Online program Deprexis, either as a stand-alone internet-based intervention (Deprexis) or with added standardized email support by a clinical psychologist (DeprexisPlus). In this trial, we will use a Version of Deprexis that has been adapted to MS-specific needs.
Study NCT01940406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stimulation procedure
Description: Device
Study NCT00251056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mannitol
Description: 120mg BD
Study NCT00251056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mannitol
Description: 40 mg BD
Study NCT00251056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mannitol
Description: 240mg BD
Study NCT00251056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mannitol
Description: 400mg BD
Study NCT03082612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faith-Based African American Cancer Survivorship Storytelling Intervention
Description: The intervention will consist of participants viewing a selection of video recorded vignettes during 3 weekly sessions. There will be 5 vignettes included in each session with each vignette edited to a real time of 3-4 minutes (each session is 30 minutes). Since the intervention is designed to be self-administered, there will be a video recorded introduction and instructions for use narrated by the PI. The vignettes are of actual African American cancer survivors narrating stories of ways in which hymns can be used to overcome their anxieties and depressed moods through the use of a hymn. The hymns included represent exemplars from the 5 themes prevalent in the PI's previous research
Study NCT04167228 — intervention group
Intervention type: DRUG
Intervention: Ceftazidime-Avibactam
Description: Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated > 2 days with ceftazidime-avibactam.
Study NCT04167228 — intervention group
Intervention type: DRUG
Intervention: Best Available Therapy
Description: Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated > 2 days with the best available treatment other than ceftazidime-avibactam.
Study NCT01001962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: empagliflozin
Description: ACTIVE TREATMENT FOR DIABETES
Study NCT01001962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: ACTIVE TREATMENT FOR DIABETES
Study NCT01280747 — intervention group
Intervention type: OTHER
Intervention: prior authorization
Description: This is a naturalistic study. The physician will prescribe medication(s) as appropriate
Study NCT01280747 — intervention group
Intervention type: OTHER
Intervention: no prior authorization
Description: This is a naturalistic study. The physician will prescribe medication(s) as appropriate
Study NCT04360798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral Exercise Group
Description: Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants exercises will only be done for 60 minutes with the affected lower extremities.
Study NCT04360798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral Exercise Group
Description: Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants will complete their exercises with both lower extremities for 30 minutes.
Study NCT03973255 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation
Description: Posturography, Whole body vibration
Study NCT04362098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visiting Program for Young Pregnant Women
Description: The visitation program was elaborated based in the following theoretical principles: a) Albert Bandura's self-efficacy theory; b) Urie Brofenbrenner's bioecological theory, which recognizes the importance of the insertion of individuals in families in varied contexts of life in society; c) John Bowlby and Mary Ainsworth's attachment theory. The basic premises of the intervention are health care, environmental health, life course development, development of parenting ability, relationship with friends and family, and social service support.
Study NCT01401114 — intervention group
Intervention type: DRUG
Intervention: E2/LNG oral (Wellnara, BAY86-5029)
Description: Patients in daily life treatment receiving Wellnara for postmenopausal osteoporosis
Study NCT04038749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Description: Bromocriptine - on the first day of treatment (1,25 mg) with morning and evening meal and then 2,5 mg dose twice a day for two weeks (14 days)
Study NCT04038749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: Cabergoline - one dose (1 mg) on the first day after childbirth or 0.25 mg dose every 12 hours for 2 days
Study NCT04038749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural methods
Description: milk expression, cold compress, cabbage leaf compresses, mild painkiller- e.g. ibuprofen, supportive bra, sage tea.
Study NCT04038749 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Natural methods
Description: milk expression, cold compress, cabbage leaf compresses, mild painkiller- e.g. ibuprofen, supportive bra, sage tea.
Study NCT02051985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-4: as days 1-2 + unloaded bedside cycle ergometer (3 sessions/day, each 5-6 minutes duration).~Days 5-6: as days 1-2 + bedside cycle ergometer at 10 W (3 sessions/day, each 15-20 minutes duration).~Days 7-12: as days 1-2 + bedside cycle ergometer at 10-20 W (3 sessions/day, each 15-20 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day.
Study NCT02051985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-12: active assisted mobilization (1 session/day, 30 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day.
Study NCT04240236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scalp block
Description: Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.
Study NCT04240236 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.
Study NCT00827775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid
Study NCT02198261 — intervention group
Intervention type: DRUG
Intervention: 5% minoxidil topical foam
Description: 5% minoxidil topical foam
Study NCT00945451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CK
Description: Cyberknife Irradiation
Study NCT01963572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SG will be screened every time when they visit the clinics.
Study NCT02604797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: patient-controlled intravenous analgesia
Study NCT02604797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: patient-controlled intravenous analgesia
Study NCT02604797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flurbiprofen axetil
Description: patient-controlled intravenous analgesia
Study NCT02604797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron
Description: patient-controlled intravenous analgesia
Study NCT00694135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGP-437 1.6 mA-min at 0.4 with EyeGate® II System
Description: Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System
Study NCT00694135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System
Description: Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System
Study NCT00694135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System
Description: Ocular Iontophoresis with EGP-437 10.0 mA-min at 2.5 mA delivered via EyeGate® II Drug Delivery System
Study NCT00694135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System
Description: Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System
Study NCT03065036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prestudy topical glaucoma medications
Description: Reintroduction of prestudy topical glaucoma medications, introduced one medication at a time during each study visit, as necessary.
Study NCT03065036 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: prestudy topical glaucoma medications
Description: Reintroduction of prestudy topical glaucoma medications, introduced one medication at a time during each study visit, as necessary.
Study NCT02939976 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Vessel Disease
Description: Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
Study NCT02939976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-vessel Disease, Culprit Vessel Only
Description: Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
Study NCT03123419 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Appointment reminders
Description: The purpose of the Gardasil study is to increase the rates of Gardasil vaccination in the Maternal Fetal Care Center. This will be done by reminding patients via text to come for their follow up vaccine appointments.
Study NCT03035318 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy Global® Anchor Peg Glenoid Instrumentation
Description: Placement of glenoid component will be performed using DePuy Global® Anchor Peg Glenoid Instrumentation.
Study NCT03035318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DePuy Global® Anchor Peg Instrumentation with SmartBone™
Description: Placement of glenoid component will be performed using DePuy Global® Anchor Peg Instrumentation with SmartBone™.
Study NCT03035318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRI with SmartBone™
Description: Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBone™.
Study NCT03035318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RTI with SmartBone™
Description: Placement of glenoid component will be performed using Real Time Instrumentation (RTI) with SmartBone™.
Study NCT03035318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRI with SmartBase
Description: Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBase.
Study NCT01095913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Description: Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
Study NCT01530087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CASTLE barrier
Description: Prototype barrier to be used in place of current two piece device
Study NCT04244422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PIEZOSURGERY VERSUS CONVENTIONAL SURGERY
Description: Piezosurgery: SATLEC ACTEON peizotome 2 (A company of ACTEON Group, France) was used. Conventional surgery with rotary instruments
Study NCT01980524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acipimox
Study NCT01980524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Study NCT02169921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atherectomy Catheter
Description: Atherectomy Catheter, TurboHawk, is used for Angioplasty. Spider FX can concomitantly be used with TurboHawk.~TurboHawkTM LS-C, TurboHawk LX-C, TurboHawk SS-CL and TurboHawk SX-C are participated in this arm.
Study NCT00690378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXL104/ceftazidime
Description: 125mg/500mg TID
Study NCT00690378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem/Cilastatin
Description: 4 x daily
Study NCT03964922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 20 ml at inclusion, and 20ml at 1, 3, 6 and 12 months after allo HSCT
Study NCT03964922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow sample
Description: 3 ml at inclusion, and 3 ml at 1, 3, 6 and 12 months after allo HSCT
Study NCT01209741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telcagepant potassium
Description: \[INTERVENTION NAME: MK-0974 12MoRT\] Single dose MK-0974 12MoRT (12 month aged MK-0974 capsules, stored at room temperature) 300 mg in one of three treatment periods
Study NCT01209741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-0974 5Mo5C
Description: Single dose MK-0974 5Mo5C (5 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
Study NCT01209741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-0974 12Mo5C
Description: Single dose MK-0974 12Mo5C (12 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
Study NCT03665753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Subject will receive 10, 20, and 30mg of Ketorolac.
Study NCT01607931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 1 hour of cycling at 50% of maximum power output
Study NCT00992121 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I
Study NCT00992121 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pazopanib 2 week
Description: Pazopanib for first 2 weeks of each 3-week cycles as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons.